Literature DB >> 9297

Evaluation of in vivo parameters of drug metabolizing enzyme activity in man after administration of clemastine, phenobarbital or placebo.

A G Hildebrandt, I Roots, M Speck, K Saalfrank, H Kewitz.   

Abstract

The 24 h urinary excretion of 6beta-hydroxycortisol and D-glucaric acid, the plasma half lives and total clearances of aminopyrine, and serum gamma-glutamyl-transpeptidase activity have been measured in nineteen healthy male volunteers. The study was done double blind and was conducted as a test of induction of microsomal drug metabolizing enzymes during and after daily doses of 6 mg clemastine, 300 mg phenobarbital or a placebo. The urinary excretion of 6beta-hydroxycortisol and D-glucaric acid was significantly increased in the phenobarbital group, the standard for induction. No changes were observed after treatment with clemastine or placebo. Phenobarbital also reduced the half life of aminopyrine, but it was not affected by clemastine or placebo. Gamma-glutamyl-transpeptidase activity increased only in the phenobarbital group. The elimination constant k2 of aminopyrine and the excretion of glucaric acid in the pre-medication period were correlated (p less than 0.05) The results indicate that the tests were of diagnostic value in determination of microsomal enzyme induction by phenobarbital. Failure to observe similar changes after treatment with clemastine imply failure of induction of this activity under the experimental conditions.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 9297     DOI: 10.1007/BF00562658

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  26 in total

1.  CHANGES IN D-GLUCARIC ACID EXCRETION INDUCED BY STIMULATORS OF ASCORBIC ACID BIOSYNTHESIS.

Authors:  C A MARSH; L M REID
Journal:  Biochim Biophys Acta       Date:  1963-12-13

2.  ALTERED CORTISOL METABOLISM IN ADVANCED CANCER AND OTHER TERMINAL ILLNESSES: EXCRETION OF 6-HYDROXYCORTISOL.

Authors:  E E WERK; J MACGEE; L J SHOLITON
Journal:  Metabolism       Date:  1964-12       Impact factor: 8.694

3.  6beta-Hydroxycortisol and other polar corticosteroids: measurement and significance in human urine.

Authors:  A G FRANTZ; F H KATZ; J W JAILER
Journal:  J Clin Endocrinol Metab       Date:  1961-10       Impact factor: 5.958

4.  The determination of 17,21-dihydroxy-20-ketosteroids in urine and plasma.

Authors:  R H SILBER; C C PORTER
Journal:  J Biol Chem       Date:  1954-10       Impact factor: 5.157

5.  The determination of enzyme inhibitor constants.

Authors:  M DIXON
Journal:  Biochem J       Date:  1953-08       Impact factor: 3.857

6.  Studies on the induction of CO-binding pigments in liver microsomes by phenobarbital and 3-methylcholanthrene.

Authors:  A P Alvares; G Schilling; W Levin; R Kuntzman
Journal:  Biochem Biophys Res Commun       Date:  1967-11-30       Impact factor: 3.575

7.  Stimulation of drug metabolism in man by tricyclic antidepressants.

Authors:  K O'Malley; M Browning; I Stevenson; M J Turnbull
Journal:  Eur J Clin Pharmacol       Date:  1973-08       Impact factor: 2.953

8.  A kinetic photometric method for serum gamma-glutamyl transpeptidase.

Authors:  G Szasz
Journal:  Clin Chem       Date:  1969-02       Impact factor: 8.327

9.  Prediction of drug oxidation rates in man: lack of correlation with serum gamma-glutamyl transpeptidase and urinary excretion of D-glucaric acid and 6 beta-hydroxycortisol.

Authors:  S E Smith; M D Rawlins
Journal:  Eur J Clin Pharmacol       Date:  1974       Impact factor: 2.953

10.  Evidence for a new P-450 hemoprotein in hepatic microsomes from methylcholanthrene treated rats.

Authors:  N E Sladek; G J Mannering
Journal:  Biochem Biophys Res Commun       Date:  1966-09-08       Impact factor: 3.575

View more
  24 in total

1.  Hepatic enzyme induction and its relationship to urinary D-glucaric acid excretion in man.

Authors:  D S Lecamwasam
Journal:  Br J Clin Pharmacol       Date:  1975-12       Impact factor: 4.335

Review 2.  Assessment of liver metabolic function. Clinical implications.

Authors:  J Brockmöller; I Roots
Journal:  Clin Pharmacokinet       Date:  1994-09       Impact factor: 6.447

3.  Measurement of urinary 6-beta-hydroxycortisol excretion as an in vivo parameter in the clinical assessment of the microsomal enzyme-inducing capacity of antipyrine, phenobarbitone and rifampicin.

Authors:  E E Ohnhaus; B K Park
Journal:  Eur J Clin Pharmacol       Date:  1979-03-26       Impact factor: 2.953

4.  Mutagenicity studies and D-glucaric acid determination in urine of workers exposed to mineral oils.

Authors:  R Pasquini; S Monarca; G S Sforzolini; A Savino; G Angeli
Journal:  Int Arch Occup Environ Health       Date:  1985       Impact factor: 3.015

Review 5.  Pharmacokinetic interactions with antiepileptic drugs.

Authors:  E Perucca
Journal:  Clin Pharmacokinet       Date:  1982 Jan-Feb       Impact factor: 6.447

6.  Urinary excretion of mutagens, thioethers and D-glucaric acid in workers exposed to bitumen fumes.

Authors:  R Pasquini; S Monarca; G Scassellati Sforzolini; A Savino; F A Bauleo; G Angeli
Journal:  Int Arch Occup Environ Health       Date:  1989       Impact factor: 3.015

7.  D-glucaric acid excretion in critical care patients--comparison with 6 beta-hydroxycortisol excretion and serum gamma-glutamyltranspeptidase activity and relation to multiple drug therapy.

Authors:  G Heinemeyer; I Roots; P Lestau; H R Klaiber; R Dennhardt
Journal:  Br J Clin Pharmacol       Date:  1986-01       Impact factor: 4.335

Review 8.  Clinical pharmacokinetic considerations in the treatment of increased intracranial pressure.

Authors:  G Heinemeyer
Journal:  Clin Pharmacokinet       Date:  1987-07       Impact factor: 6.447

Review 9.  Drug interactions with St John's wort : mechanisms and clinical implications.

Authors:  Marcus Mannel
Journal:  Drug Saf       Date:  2004       Impact factor: 5.606

10.  Kinetics of hexobarbital and dipyrone in critical care patients receiving high-dose pentobarbital.

Authors:  G Heinemeyer; H J Gramm; W Simgen; R Dennhardt; I Roots
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.